Stock Market Reviews

RCKT (Rocket Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on RCKT (Rocket Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery
  Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best single digit stocks to buy according to analysts. On January 8, Morgan Stanley lowered its price target for Rocket Pharmaceuticals from $7 to $5 while keeping an Equal Weight rating. In a 2026 group outlook, the firm noted it expects continued outperformance for US small-to-mid cap […]
  Feb 19, 2026 - $RCKT
• Undervalued Penny Stocks To Consider In January 2026
  As the U.S. stock market begins a busy week of tech earnings and interest rate decisions, major indexes have seen gains following two weeks of losses, with gold reaching new heights amid geopolitical tensions. In this context, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for investors willing to explore beyond the mainstream. Despite their vintage name, these stocks can provide significant potential for growth when backed by strong...
  Jan 26, 2026 - $RCKT
• Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
  CRANBURY, N.J., January 05, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference, in San Francisco. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Wednesday, January 14, at 11:15 a.m. PT and host investor meetings throughout th
  Jan 5, 2026 - $RCKT
• Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders
  As the year draws to a close, U.S. markets are experiencing volatility, with major indexes closing lower amid concerns about an AI bubble and looming economic reports. In such a climate, investors often look beyond the large-cap stocks dominating headlines to explore opportunities in lesser-known areas like penny stocks. While the term "penny stocks" may seem outdated, it continues to signify smaller or emerging companies that could offer significant value when backed by strong financials and...
  Dec 17, 2025 - $RCKT
• Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position
  Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the stocks that will double in 2026. Earlier on November 18, BofA lowered the firm’s price target on Rocket Pharmaceuticals to $8 from $10 and kept a Buy rating on the shares following an updated cash position that was made after the company announced its Q3 2025 update. […]
  Dec 16, 2025 - $RCKT
• Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
  CRANBURY, N.J., November 25, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings.
  Nov 25, 2025 - $RCKT
• Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand
  **Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increased cancer risk due to DNA repair defects. Although incurable, treatments like bone marrow transplants and gene therapy aim to manage FA's symptoms. The rising prevalence of genetic disorders and advancements in genetic research drive the FA market. Key players such as Rocket
  Nov 18, 2025 - $RCKT
• Amazon downgraded, Alphabet upgraded: Wall Street's top analyst calls
  Amazon downgraded, Alphabet upgraded: Wall Street's top analyst calls
  Nov 18, 2025 - $RCKT
• Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer
  Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, today announced the appointment of Carlos Martin as Chief Commercial Officer (CCO). Martin brings more than 20 years of leadership experience across global biopharmaceutical markets, with a proven record of building commercial organizations, launching transformative therapies, and strengthening pipeline valuation in highly innovative areas such as gene therapy, radiopharma, oncology, cardiology, and rare d
  Nov 13, 2025 - $RCKT
• Leukocyte Adhesion Deficiency Market Analysis and Forecast, 2025-2035, Featuring Rocket Pharmaceuticals, Avalo Therapeutics, Orpha Labs, and AUG Therapeutics
  The market is driven by advancements in gene therapy, stem cell-based treatments, and increasing investment in rare diseases. Despite high costs, the market for these innovative treatments is growing, especially in regions with improved healthcare systems.Dublin, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The "Leukocyte Adhesion Deficiency Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The leukocyte adhesion deficiency market
  Nov 12, 2025 - $RCKT